Research
How to read an FDA warning letter
A warning letter is an allegation and an invitation to respond. FDA calls it informal and advisory, and says it is not final agency action, which is a long way from the verdict it is usually read as.
What the document is
FDA describes a warning letter as its principal means of achieving prompt voluntary compliance with federal food and drug law. The agency issues one when it believes it has found violations of regulatory significance, meaning violations that could lead to enforcement action if not corrected.
The agency is explicit about the letter's legal weight. Its own procedures manual states that a warning letter is informal and advisory. The manual adds that a letter communicates the agency's position without committing FDA to enforcement, and that FDA does not treat warning letters as final agency action on which it can be sued.
A letter is also not a prerequisite to enforcement. FDA states it is under no legal obligation to warn a firm before acting. It lists circumstances where it will skip the letter entirely, including repeated conduct after prior notice and violations presenting a reasonable possibility of injury or death.
What a letter alleges, and what it does not
FDA describes the concerns a warning letter identifies as things like poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use.
Those fall into two families that get conflated constantly. One is about how a product was made: sanitation, process controls, testing, record-keeping. The other is about how a product was described: the claims on a website, the wording on a label, the instructions supplied with it.
A letter in the second family is a statement about words. It is not a laboratory result, and it is not evidence that anything was found in a vial. Reading the subject line and the section headings tells you which family you are looking at in about ten seconds.
Neither family makes a letter a safety finding. A letter records what FDA believes it has found and asks the recipient to fix it.
What a letter to a peptide seller looks like
An August 2026 letter from FDA's drug center to a peptide vial seller shows the shape of the most common allegation in this market, and none of it is about the contents of a vial.
The violation cited is selling unapproved new drugs. The reasoning runs in three steps.
The products are drugs, because the website's own text shows they are intended to affect the structure or function of the body. They are new drugs, because they are not generally recognized as safe and effective under the conditions suggested in their labeling. And no approved application exists for them, so shipping them across state lines violates the statute.
The evidence quoted is the seller's own marketing copy: benefit lists, weight-loss percentages attributed to trials, and descriptions of what each peptide is studied for.
A footnote handles the research-use-only disclaimer directly. FDA writes that despite labeling the products for research use only and not for human or animal consumption, evidence from the website establishes they are intended to be drugs for human use. The letter adds that the seller marketed bacteriostatic water alongside a peptide guide and a peptide calculator, resources that together supply the means to prepare an injectable drug for human administration.
The letter is the start of a conversation
Every warning letter asks for a written response, typically within fifteen business days, describing the corrective steps taken and how recurrence will be prevented.
The recipient can also disagree. FDA invites a firm that believes its products are not in violation to submit that information for consideration, and its guidance notes a recipient may supply its reasoning and supporting information.
That is why the warning letter index carries a standing caveat. Matters described in a letter may have been subject to subsequent interaction between FDA and the recipient, which can change the regulatory status of the issues discussed.
A letter published two years ago describes what FDA believed two years ago. It does not describe today unless nothing has happened since, and the letter itself cannot tell you which.
Close-out letters, and what their absence means
FDA may issue a close-out letter once it has evaluated a firm's corrective actions and concluded the violations have been addressed. The program applies to warning letters issued on or after September 1, 2009.
The standard is strict. A close-out letter will not issue based on a promise that action will be taken; the corrections must actually have been made and verified, usually through a follow-up inspection.
The absence of a close-out letter is therefore ambiguous, and this is where readers most often go wrong. It can mean corrections were never verified. It can also mean the violations were of a kind that cannot be corrected after the fact, in which case FDA states no close-out letter will issue at all.
A close-out letter is good evidence when present. Its absence is weak evidence of anything.
Six things to check before drawing a conclusion
Read the subject line. It names the alleged violation category, and it separates a manufacturing allegation from a claims allegation immediately.
Read the issue date and the posted date, and ask what has happened since. Enforcement records age fast.
Read which office issued it. A letter from the drug center about website claims and a letter from a field office after an inspection are different instruments with different evidence behind them.
Read what was actually quoted as evidence. Website copy is evidence about marketing. Inspection observations are evidence about a facility.
Check whether a response or close-out letter is listed alongside the letter in the index, and read those too.
Then ask the only question that matters for a decision: does the allegation describe something that changes what a patient receives, or does it describe how a product was advertised?
How this site uses letters
A letter is disclosed where one exists, with what it concerned stated plainly. It never moves a score, a verdict or a ranking position.
A letter is an allegation about conduct at a moment in time, and most often about words rather than substances. It is subject to a response the reader usually cannot see, and it is sometimes resolved without any public marker.
Treating that as a safety rating would import a precision the document does not have. Disclosing it and letting a reader weigh it is the honest use.
Key takeaways
- FDA calls a warning letter informal and advisory, and does not treat it as final agency action.
- The concerns it names span manufacturing practices, product claims, and directions for use.
- An unapproved-new-drug allegation is about legal status and marketing claims, not vial contents.
- A research-use-only disclaimer did not defeat an intended-use finding in an August 2026 peptide letter.
- Recipients get roughly fifteen business days to respond, and may contest the findings.
- A close-out letter requires verified correction; its absence can mean the violations were not correctable.
Frequently asked questions
Does an FDA warning letter mean a product is unsafe?
No. FDA describes a warning letter as informal and advisory, communicating the agency's position without committing it to enforcement, and states it is not final agency action. The concerns it identifies range from manufacturing practices to claims about what a product can do to incorrect directions for use. A letter about marketing language is a statement about words, not a laboratory finding about a vial.
What does "unapproved new drug" mean in a warning letter?
That FDA considers the product a drug, because its labeling shows it is intended to treat a condition or affect the structure or function of the body, and that no approved application exists for it. Under federal law a new drug cannot be shipped across state lines without an approved application. The allegation is about legal status and marketing claims, not about what a laboratory found in the product.
Does a "research use only" label protect a seller?
Not on its own. In an August 2026 letter to a peptide vial seller, FDA addressed that disclaimer directly. Despite labeling the products for research use only and not for human or animal consumption, evidence from the website established they were intended to be drugs for human use. The agency cited the marketing claims themselves, and the sale of bacteriostatic water alongside a peptide guide and a peptide calculator.
If a company got a warning letter, has the problem been fixed?
The letter cannot tell you. FDA asks for a written response, usually within fifteen business days, and states that subsequent interaction may have changed the regulatory status of the issues discussed. A close-out letter is issued only after FDA verifies corrections, usually by follow-up inspection, and it is not issued at all where violations are not correctable by their nature. So the absence of one is ambiguous rather than damning.
Why does a warning letter not lower a provider's ranking here?
Because it is an allegation about conduct at a point in time, most often concerning marketing and labeling rather than the contents of a medication. The response and its outcome are also usually invisible to a reader. Letting a document with that shape drive a score would give it a precision it does not have. Where a letter exists it is disclosed, with what it concerned stated plainly, and the reader weighs it.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- Regulatory Procedures Manual, Chapter 4: Advisory Actions, section 4-1-1 Warning Letter Procedures — U.S. Food and Drug Administration, July 2024
- About Warning and Close-Out Letters — U.S. Food and Drug Administration, March 2024
- Warning Letters index, with the standing note that subsequent interaction may have changed regulatory status — U.S. Food and Drug Administration, September 2026
- Warning Letter to Royal Peptides LLC, reference 734884, Center for Drug Evaluation and Research — U.S. Food and Drug Administration, August 2026